Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 17/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20680278 | 0.84 | CD38 (0.55) | CD38GAAMAPTCYP3A4KCNH2 | |
| SCHEMBL3052328 | 0.83 | GAA (0.52) | CD38GAAMAPTCYP3A4KCNH2 | |
| SCHEMBL20680206 | 0.82 | CD38 (0.54) | CD38GAAMAPTCYP3A4KCNH2 | |
| SCHEMBL20680320 | 0.82 | CD38 (0.53) | CD38CYP3A4KCNH2MEN1KMT2A | |
| SCHEMBL20680330 | 0.82 | CD38 (0.66) | CD38GAAMAPTCYP3A4KCNH2 | |
| SCHEMBL20680210 | 0.81 | CD38 (0.80) | CD38CYP3A4KCNH2 | |
| SCHEMBL20680296 | 0.81 | CD38 (0.54) | CD38GAAMAPTCYP3A4KCNH2 | |
| SCHEMBL20680443 | 0.80 | CD38 (0.66) | CD38GAAMAPTCYP3A4KCNH2 | |
| SCHEMBL20680407 | 0.80 | CD38 (0.71) | CD38GAAMAPTCYP3A4KCNH2 | |
| SCHEMBL20680289 | 0.79 | CD38 (0.60) | CD38GAAMAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087290-A1 | COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | ENCEFA (FR) | 2021-03-25 | — | — | US | disclosed |
| EP-3658586-A1 | COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | ENCEFA (FR) | 2020-06-03 | — | — | EP | disclosed |
| CN-111108127-A | Compounds that specifically bind CD38 for use in the treatment of neurodegenerative and inflammatory diseases | ENCEFA公司 | 2020-05-05 | — | — | CN | disclosed |
| WO-2019020643-A1 | COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | ENCEFA (FR) | 2019-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087290-A1 | COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | CD38, TRPC1, TRPC4 | CD38 1/4885GAA 763/4885MAPT 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.